{"url_path":"/sec/sabsw/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1833214/0001193125-26-218195-index.html","accession_number":"0001193125-26-218195","cik":"0001833214","ticker":"SABS","issuer_name":"SAB Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1833214/0001193125-26-218195-index.html","primary_entity_key":"0001833214","primary_entity_name":"SAB Biotherapeutics, Inc."},"word_count":419,"has_tables":true,"body_markdown":"## Item 6. Exhibits.\n\nExhibit Number\n\nDescription\n\nSchedule/\n\nForm\n\nFile No.\n\nExhibit\n\nFiling Date\n\n4.1\n\n[Form of Pre-Funded Warrant](https://www.sec.gov/Archives/edgar/data/0001833214/000119312526114730/sabs-ex1_1.htm)\n\n8-K\n\n001-39871\n\n4.1\n\nMarch 19,2026\n\n10.1\n\n[Underwriting Agreement, dated March 17, 2026, by and between SAB Biotherapeutics, Inc. and Jefferies LLC, UBS Securities, LLC, Citigroup Global Markets Inc., and Barclays Capital Inc. as representatives of the several underwriters named therein.](https://www.sec.gov/Archives/edgar/data/0001833214/000119312526114730/sabs-ex4_1.htm)\n\n8-K\n\n001-39871\n\n1.1\n\nMarch 19, 2026\n\n10.2*\n\n[Sanford Lease Amendment, dated April 1, 2026](sabs-ex10_2.htm)\n\n \n\n \n\n \n\n \n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](sabs-ex31_1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](sabs-ex31_2.htm)\n\n32.1**\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](sabs-ex32_1.htm)\n\n32.2**\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](sabs-ex32_2.htm)\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF\n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB\n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n \n\n \n\n \n\n \n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n* Filed herewith.\n\n** The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report are not deemed filed with the SEC and are not to be incorporated by reference into any filing of SAB Biotherapeutics, Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing.\n\n¥ Denotes management contract or any compensatory plan, contract or arrangement.\n\n39\n\n \n\nSIGNATURES\n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\nSAB BIOTHERAPEUTICS, INC.\n\nDate: May 12, 2026\n\nBy:\n\n/s/ Samuel J. Reich\n\nSamuel J. Reich\n\nChief Executive Officer\n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Lucy To\n\n \n\n \n\n \n\nLucy To\n\n \n\n \n\n \n\nChief Financial Officer\n\n(Principal Financial Officer and Principal Accounting Officer)\n\n \n\n40"}